Eli Lilly and Company (NYSE:LLY) Shares Bought by Naviter Wealth LLC

Naviter Wealth LLC grew its position in Eli Lilly and Company (NYSE:LLY) by 9.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,650 shares of the company’s stock after purchasing an additional 319 shares during the quarter. Naviter Wealth LLC’s holdings in Eli Lilly and Company were worth $2,128,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Bluesphere Advisors LLC grew its position in shares of Eli Lilly and Company by 98.5% during the fourth quarter. Bluesphere Advisors LLC now owns 1,209 shares of the company’s stock worth $705,000 after acquiring an additional 600 shares during the last quarter. Choreo LLC boosted its stake in shares of Eli Lilly and Company by 35.3% during the fourth quarter. Choreo LLC now owns 8,643 shares of the company’s stock worth $5,038,000 after buying an additional 2,257 shares during the period. McAdam LLC increased its position in Eli Lilly and Company by 5.6% in the 4th quarter. McAdam LLC now owns 1,590 shares of the company’s stock valued at $927,000 after acquiring an additional 84 shares during the period. Mitchell Mcleod Pugh & Williams Inc. raised its stake in Eli Lilly and Company by 0.8% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 7,282 shares of the company’s stock valued at $4,245,000 after acquiring an additional 60 shares during the last quarter. Finally, Capital Investment Counsel Inc lifted its position in Eli Lilly and Company by 20.6% during the 4th quarter. Capital Investment Counsel Inc now owns 603 shares of the company’s stock worth $352,000 after acquiring an additional 103 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. BMO Capital Markets upped their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research report on Friday, March 22nd. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, Morgan Stanley boosted their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $0.26 during trading on Monday, hitting $733.77. 1,315,541 shares of the stock were exchanged, compared to its average volume of 2,999,455. The stock has a market cap of $697.20 billion, a PE ratio of 126.34, a P/E/G ratio of 1.60 and a beta of 0.34. The stock’s fifty day moving average is $761.79 and its 200 day moving average is $667.10. Eli Lilly and Company has a 12 month low of $392.26 and a 12 month high of $800.78. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter last year, the business earned $2.09 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.